Unifire will focus on distribution to government agencies and humanitarian efforts
VANCOUVER, BRITISH COLUMBIA, CANADA – TheNewswire – MARCH 22, 2022 – Mission Ready Solutions Inc. (“Ready for the mission“or the”Company“) (TSXV:MRS) (OTC: MSNVF) (FSE: 2R4), a provider of global government contracting solutions, is pleased to announce that, through its wholly owned subsidiary, Unifire, Inc. (“Unifire“), the Company has entered into a framework distribution and marketing agreement (the “OK“) with NuGen MD (TSX-V: NGMD) (“NuGen“), an emerging specialty medical device company focused on the development and commercialization of novel drug delivery technologies.
As part of the agreement, Unifire was granted exclusive rights to sell NuGen’s InsuJet™ needle-free injection device to various U.S. government agencies and non-exclusive rights to sell to government agencies in Israel and Australia. Unifire will act as NuGen’s primary distributor in the United States with an immediate focus on opportunities within the Department of Defense (DoD), Biomedical Advanced Research and Development Authority (BARDA), Defense Advanced Research Projects Agency (DARPA), Veterans Affairs (VA), Department of Homeland Security (DHS), and Health and Human Services (HHS).
The NuGen InsuJet™ Needle-Free Injection System is a revolutionary needle-free way to inject drugs or vaccines and:
Provides faster drug absorption than hypodermic needles
Reduces fear and anxiety associated with hypodermic needles
Eliminates needlestick injuries
Reduces the risk of cross contamination and infections
Reduces the financial burden on the health care system
Reduces costs for patients
Reduces biohazardous waste
“We are thrilled to have Unifire join our global network of distributors with their deep understanding of the government contracting space, proven relationships and track record of execution,” said Michael Wright, CEO of NuGen. “Unifire will support NuGen in achieving its strategy of expanding into the US market by focusing on the acceptance of InsuJet™ as a safe, reliable and cost-effective replacement for the current standard of injecting drugs into the breast. of Unifire’s established customer base of government agencies.
Unifire will work with NuGen to secure regulatory approval, gain political support, introduce non-dilutive government funding, while advising on the necessary manufacturing and supply chain requirements to be eligible to submit tenders. governmental.
“A device with the demonstrated ability to safely, quickly and effectively deliver critical medications has the potential to create a paradigm shift in the current standard of care in place within government agencies,” said Douglas Bryce, Member of the Mission Ready Advisory Board and topic. expert in the development, acquisition, distribution and deployment of chemical, biological, radiological and nuclear (CBRN) defense devices and medical diagnostic systems, drugs and vaccines. “I strongly believe that there are significant opportunities for the deployment of new and disruptive solutions within the Department of Defense, government-run medical facilities, and their adoption in tactical combat casualty care.”
Together, the companies will focus on opportunities within:
Immediate humanitarian efforts to provide safe access to insulin treatments
Global immunization efforts
Biomedical Advanced Research and Development Authority (BARDA)
Defense Advanced Research Projects Agency (DARPA)
Veterans Affairs (VA) for acceptance to meet health care needs
DoD or government agencies with medical facilities
Inclusion in Tactical Combat Casualty Care (TCCC)
Dan Raczykowski, COO of Unifire, added, “Unifire prides itself on providing the best technologies that can provide solutions to critical needs. NuGen’s needle-free device, with regulatory approval in over 40 countries, could open up new opportunities within our network, especially in times of need for humanitarian assistance where access to life-saving medicines is a challenge. logistics for select populations. We are excited to join NuGen’s list of global distributors while supporting their team on the path to US regulatory approval. “
About the InsuJet™
The InsuJet™ is a revolutionary needle-free medication delivery device used to self-administer medication safely, fearlessly and virtually painlessly. Its use is now approved in more than 40 countries worldwide.
About NuGen Medical Devices
NuGen Medical Devices’ core business is the development and commercialization of innovative needle-free injection devices and systems for subcutaneous drug delivery.
It develops products using needle-free drug delivery technology in several important areas, including but not limited to anaphylaxis, diabetes, severe migraine, erectile dysfunction, chronic anemia, neutropenia, autoimmune rheumatoid arthritis, growth and fertility hormone, psoriasis as well as DNA and conventional/pediatric vaccines.
About Mission Ready Solutions Inc.
Mission Ready Solutions provides comprehensive government contracting solutions with extensive experience in delivering quality, reliable and mission-critical products and services to law enforcement, fire, first responders, military and emergency services. other government agencies.
With its privileged access to a host of federal contracting vehicles, including the multiple award schedule (“SAM“) contracts awarded and administered by the United States General Services Administration, Mission Ready’s wholly-owned subsidiary, Unifire, Inc., leverages its robust supplier network, proven industry relationships, infrastructure exclusive technological and industry-state-of-the-art manufacturing and distribution capabilities to efficiently source and deliver over 1.5 million products.
For more information about Mission Ready Solutions Inc., please visit MRSCorp.com.
You can also subscribe to our mailing list at eepurl.com/hznhX9 to receive our press releases and our latest news directly by email.
Mission Ready Solutions Inc.
(Signed “Buck L. Marshall”)
Buck L. Marshall
President, CEO and Director
Phone. : +1 877.479.7778
Contact with Investor Relations:
Phone. : +1 877.479.7778 (ext. 5)
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”. , “plan”, “project”, “budget”, “schedule”, “may”, “will”, “could”, “could”, “should” or variations of these words or similar words or expressions. Forward-looking information is based on reasonable assumptions made by Mission Ready Solutions Inc. as of the date of this information and is subject to known and unknown risks, uncertainties and other factors that may cause actual results, level of activity, performance or achievements of Mission Ready Solutions Inc. are materially different from those expressed or implied by such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Mission Ready Solutions Inc. does not undertake to update any forward-looking information included herein, except in accordance with applicable securities laws.